MDCX: Medicus Pharma Limited Company Value to Net Income

Corporate emblem and logo of Medicus Pharma Limited (MDCX)

Medicus Pharma Ltd. (MDCX) acts as a medical innovator, developing targeted injections against skin cancer as an alternative to surgery. Low geopolitical risks and the absence of trade barriers ensure operational stability across developed nations. This chart shows a market price corresponding to a P/E multiple of -0.10. The brand is also recognized as a reliable dermatology researcher whose safe testing of new drugs is highly valued by practicing physicians.

Medicus Pharma Ltd. (MDCX) Price to Earnings Ratio: for the period 11/15/2024 - 11/13/2026

Analytical breakdowns for Medicus Pharma Ltd.

- price and consensus price forecast:
Stock Price medicuspharma.com|MDCX - Consensus Target
- market capitalization information:
Market Value Medicus Pharma Ltd.|MDCX - Total Company Value
- balance sheet net asset value indicators:
Net Assets per Share Medicus Pharma|MDCX - Company Book Value|Market Capitalization to Book Value Ratio medicuspharma.com|MDCX - Company Total Assets
- company liabilities and liquidity data:
Total Debt to Capital Coefficient Medicus Pharma Ltd.|MDCX - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Medicus Pharma Corp|MDCX - Company Debts|Debt to Book Value Medicus Pharma Ltd.|MDCX - Company Long-Term Debts|Short-Term Debt Medicus Pharma|Immediate Liquidity Ratio medicuspharma.com
- earnings and market multiples details:
MDCX - Net Profit|Company Profit Forecast Medicus Pharma Ltd.|MDCX - P/E Multiple|Projected Price to Earnings Medicus Pharma Ltd|MDCX - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Medicus Pharma Ltd.|MDCX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Medicus Pharma|MDCX - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months medicuspharma.com|MDCX - Earnings per share growth in current year|Net earnings per share change forecast for next year Medicus Pharma Ltd.
- sales volume and revenue indicators:
MDCX - Revenue and Sales Volume|Company Future Revenue medicuspharma.com|MDCX - P/S Multiple|Forward P/S Multiple Medicus Pharma Ltd.
Comprehensive company analysis:MDCX medicuspharma.com
Manufactured product of medicuspharma.com

Investors are assessing the resilience of Medicus Pharma Ltd. (MDCX) through the lens of the price-to-earnings ratio, which is critical given the complex logistics of clinical trials for dermatological drugs. By analyzing the company's P/E volatility, one can determine the degree of business overvaluation relative to government bond yields, identifying capital impairment risks during periods of inflationary spikes or recession.

Key competitors

P/E Multiple krystalbio.com|Price to Earnings Ratio APGE (Apogee Therapeutics, Inc.)|ARQT (Arcutis) - Company Value to Net Income|Price to Earnings Ratio Vericel Corp. VCEL|Business Payback Period Oruka Pharma (ORKA)|SMTI - Price to Earnings Ratio|DBVT - P/E Multiple|SLSN: P/E Multiple|DERM - Business Payback Period|Price to Earnings Ratio Forte Biosciences, Inc|Price to Earnings Multiple EMPG (Empro Corporation)|Price to Earnings Ratio Sol-Gel Technologies (SLGL)|Price to Earnings Ratio reviveprocare.com AXIL|P/E Multiple VRCA (Verrica Pharmaceuticals Inc.)|Hoth Therapeutics Inc. (HOTH) - Market Cap to Earnings|Biofrontera Inc - P/E Multiple|VYNE (VYNE Therapeutics) - Price to Earnings Multiple|SNOA: P/E Multiple|QNRX - Business Payback Period|AZTR (Azitra) - P/E Multiple|Price to Earnings Ratio Dermata Therapeutics Inc (DRMA)|Price to Earnings Ratio ELAB (Elevai Skincare)|P/E Multiple Revance Therapeutics Inc (RVNC)